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RESULTS: The cost model generated an estimated retail price of
€55 or €113 for the neck brace depending on assumptions. The
estimated retail price for the neck brace was lower than the
reimbursement tariff of €194 and the actual retail price of €241.
With respect to the knee brace, the estimated retail price of €331
or €523 was inferior to the tariff of €580 and the actual retail
price of €948. CONCLUSION: Actual retail prices and reim-
bursement tariffs for two selected neck and knee braces substan-
tially exceeded retail prices based on estimated production and
distribution costs. Therefore, there seems to be scope for reduc-
ing reimbursement tariffs and containing public expenditure on
orthotic braces.
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OBJECTIVE: The Israeli National Health Insurance Law stipu-
lates aNational List ofHealth Services (NLHS)which all residents
are entitled from their HMOs. This list has been updated annually
for almost a decade using a structured review and decision-making
process. Although the Israeli explicit priority-setting experience is
unique and may be considered groundbreaking, its fairness and
legitimacy have not been assessed. To assess the priority-setting
process for compliance with the four conditions of accountability
for reasonableness outlined by Daniels and Sabin (relevance,
publicity, appeals, and enforcement), andwith the four steps of the
trans-disciplinary model for priority setting in health care (rea-
sonableness, transparency, responsiveness, and accountability).
METHODS: We used such data as public documents, audit
reports, literature review, the mass media, observations from the
meetings of the Public Adivosry Committee responsible for rec-
ommending new technologies for th NLHS, and interviews with
the committeemembers.RESULTS:The Israeili process for updat-
ing the NLHS does not fulﬁll the appeals and enforcement
conditions, and only partially follows the publicity and relevance
conditions, outlinesd in the accountabilty for reasonableness and
transparency framework. Only the reasonableness and transpar-
ency steps of the trans-disciplinary model are partially fulﬁlled,
but the priority setting process lacks responsiveness and account-
ability. CONCLUSION: The fairness and legitimacy of the
priority-setting mechanism have not been established. The main
obstacles for achieving these goals may relate to the large number
of technologies assessed each year within a short time frame (500
technologies assessed in 2007), the lack of personnel engaged in
health technology assessment and the desire for early adoption of
new technologies. Changes in the priority-setting process should
be made in order to increase its acceptability among the different
stakeholders.
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OBJECTIVE: Stakeholder involvement in health technology
assessment (HTA) is of growing importance, as their participa-
tion in and support of economic evaluation is generally con-
sidered to improve the assessment process and subsequent
implementation. Consequently, in early 2007, the Health Select
Committee of the UK House of Commons initiated a public
inquiry into the National Institute of Health and Clinical Excel-
lence (NICE), calling for comments from a variety of stake-
holders. This study aimed to examine stakeholder perspectives
on several topics, including public conﬁdence in NICE; appro-
priateness of economic evaluation methods; and, effectiveness of
guidance implementation. METHODS: All stakeholder submis-
sions (n = 92) were systematically reviewed and key themes were
identiﬁed across three principal categories: 1) organisation and
process; 2) methods; and 3) decision-making and implementa-
tion. RESULTS: Stakeholders identiﬁed a number of overarching
issues regarding NICE and economic evaluation, more broadly.
Firstly, despite its “arms-length” organisational structure, NICE
is perceived to lack independence. Secondly, stakeholders con-
tented that its methods assume an overly narrow perspective,
especially regarding the use of RCTs, QALYs, and measures of
costs and beneﬁts. Thirdly, commentators asserted that manufac-
turers, clinical experts, and patients should play a greater role in
HTA processes. Fourthly, the time taken to issue guidance was
considered an important limitation, especially given evidence
that local decision-makers delay the introduction of new treat-
ments pending NICE’s decision(s). Other key concerns included
inconsistent local implementation of guidance and the overall
transparency of NICE operations. CONCLUSION: Most stake-
holders support the overall role of NICE in the NHS, and
acknowledge that the Institute generally undertakes rigorous
assessments. Nevertheless, many criticisms were put forth by
stakeholders. NICE should continue to capitalise on its strengths,
while pioneering solutions to address existing limitations and
challenges. However, it is unlikely that any national HTA system
will satisfy the needs and expectations of all key parties.
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OBJECTIVE: To evaluate a methodology of managing high cost
patients, called Case Management Program (CMP), within a
private health plan in southern Brazil and show that such
program is cost-effective and the return on investment (ROI) is
positive. METHODS: Using NAGIS(c) model and software for
disease management program, the CMP was implemented in
211 patients (0.9% of the health plan beneﬁciaries). I compared
health plan utilization and costs including CMP costs of one
period of time before the program starts with the same period of
time that the program was in place. RESULTS: After 9 months of
CMP, there were 162 patients. I considered outcomes for these
162 patients. For one Real invested, R$4,78 was saved (One
2008 American Dollar is 1,78 Brazilian Real). The average cost
per enrollee per month reduced 45.9% (R$463,85 to R$250,89)
and 39.4% (R$463,85 to R$280,90) if the program’s costs
(direct and indirect costs) are included as ﬁxed costs. The number
of visits reduced by 11.3% (794 to 704), as well as the labs
exams which reduce 35.7% (420 to 270). Nevertheless, the labs
exams per visit index reduce by 27.5%, where almost 53% of the
visits had at least one exam before starting the program against
38.3% after the same period of time that the program starts. The
number of hospitalizations reduced 34.6%, from 483 to 316.
Thus, the bed-days saved were 554 days at inﬁrmaries and 62
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days at intensive care unit. The incremental cost per bed-day
saved was R$419,66. CONCLUSION: The NAGIS(c) model of
managed high cost patient, called Case Management Program is
cost-effective where the incremental cost per bed-day saved is
$419,66, and its return of investment is highly positive.
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OBJECTIVE: The purpose of this analysis was to develop a
method for identifying Medicare Part D members with cardio-
vascular disease using medication proxies. METHODS: A binary
matrix was created from cardiovascular medication prescription
claims for Medicare Part D MAPD and commercial members
from the ﬁrst quarter of 2007. The binary matrix was subjected
to factor/principal component analysis. The maximum valued
factor loading for each of the generated components were then
used to create a member/factor loading matrix. This matrix was
used to derive beta coefﬁcients, from logistic regression, to cal-
culate a member’s probability of having hypertension, CAD, or
CHF. RESULTS: One-hundred and twelve factors were produced
over 696,471 members prescribed cardiovascular medications.
Different probability thresholds were evaluated to determine the
sensitivity and speciﬁcity for the identiﬁcation method. The
threshold probabilities ran from >0.30 to >0.975. As the thresh-
old probabilities increased, sensitivity/speciﬁcity for hyperten-
sion, CAD, and CHF ran from 0.99/0.50–0.50/0.99, 0.61/0.91–
0.50/0.99, and 0.63/0.96–0.50/0.99, respectively. A similar result
was produced using maximum score coefﬁcients resulting from
the principal component analysis. CONCLUSION: Although
this approach to identifying members with medication proxies
appears to separate members with and without certain cardio-
vascular conditions, it tends to exclude members at the cost of
minimizing erroneously identiﬁed members.
HEALTH CARE USE & POLICY STUDIES—Drug Use
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OBJECTIVE: Some contend that prescription copayment
increases reﬂect a disproportional shifting of costs to members
while others believe that copayments are simply keeping pace
with rising prescription costs. To better understand the drivers of
prescription cost sharing, this analysis examines recent trends
in member copayments relative to total prescription costs.
METHODS: The study is a retrospective descriptive analysis of
prescription claims data for a sample of commercially-insured
members enrolled with Express Scripts between 2002 and 2006.
Plan sponsors included in the analysis offered integrated prescrip-
tion coverage within an employer-based market (no Medicare or
Medicaid). For each year, the data represent prescription claim
activity for over 18 million members. Total per-prescription costs
were calculated as the sum of the discounted ingredient cost,
dispensing fee, administrative fees and any applicable tax divided
by the number of 30-day equivalent prescriptions. Average
member per-prescription cost was calculated as the total member
cost divided by the total number of 30-day equivalent prescrip-
tions. Costs were calculated separately for generics, preferred
brands and non-preferred brand-name prescriptions. RESULTS:
From 2002 to 2006 the average total per-prescription cost
increased $10.23 or 20.5% while the average member per pre-
scription copayment increased by $1.70 or 14.3%. The propor-
tion of total costs paid by members decreased from 24% in 2002
to 23% in 2006. Per-prescription member costs increased by
10% for generics, 25.7% for preferred brands and 58.6% for
non-preferred brands. CONCLUSION: These ﬁndings suggest
that plan sponsors are not shifting a greater proportion of costs
to members, nor is member cost share keeping pace with rising
prescription costs. Actual per-prescription member cost share
increased at a modest rate, inﬂuenced by increased generic use
which grew from 42% in 2002 to 58% in 2006.
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OBJECTIVE: The aim of this study was to evaluate trends in the
use of herbs and dietary supplements (HDS) in relation to pre-
scription drug (Rx) use, as well as their individual use, among US
adults from 1999–2004. METHODS: Data were abstracted from
the 1999–2000 and 2003–2004 cycles of the National Health
and Nutrition Examination Survey (NHANES). HDS included
herbs, vitamins, minerals, and other supplements. Trends in HDS
and/or Rx use were examined based on stratiﬁed characteristics
(i.e., sociodemographics, insurance coverage, health care visits
during the preceding year, chronic conditions). Sampling weights
were adjusted to allow for the pooling of data from multiple
waves. RESULTS: Overall, the proportion of HDS users
increased from 51.2% during 1999–2000 to 53.0% during
2003–2004, while that of Rx users increased from 49.9% to
55.6% over the same period. Between 1999 and 2004, the pro-
portion of HDS-only users decreased while the proportion of
people who only used Rx increased. The concomitant use of HDS
and Rx increased for most subgroups, except for those who had
an annual household income less than $14,999 or greater than
$65,000, and who had never have health care visits during the
preceding year. CONCLUSION: Trends suggest that concomi-
tant HDS and Rx use increased over the period of observation in
the general US population. Further research is needed to inves-
tigate the outcomes of concurrent HDS and Rx use.
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OBJECTIVE: Drug expenditures have been increasing much
faster than spending on other medical services and have become
burdensome for state Medicaid programs. This study was to
analyze the trends of Medicaid drug utilization and expenditures
across all major therapeutic classes and to identify their similari-
ties and differences. METHODS: Quarterly Medicaid reim-
bursed drug prescriptions and dollar amounts for each drug were
extracted from the national claims data from the Centers for
Medicare & Medicaid Services for 1991 through 2004. Expen-
ditures were aggregated across all drugs in 64 different therapeu-
tic classes, providing 64 different time series of length 56 quarters
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